| 1 | neurodegenerative and other misfolded | | | | | | | 3 | 0.84% |
| 2 | view press release apr | | | | | | | 2 | 0.56% |
| 3 | other misfolded protein diseases | | | | | | | 2 | 0.56% |
| 4 | and other misfolded protein | | | | | | | 2 | 0.56% |
| 5 | apr 30 2024 promis | | | | | | | 1 | 0.28% |
| 6 | company latest news view | | | | | | | 1 | 0.28% |
| 7 | publishes study highlighting oligomer | | | | | | | 1 | 0.28% |
| 8 | is committed to the | | | | | | | 1 | 0.28% |
| 9 | committed to the discovery | | | | | | | 1 | 0.28% |
| 10 | to the discovery and | | | | | | | 1 | 0.28% |
| 11 | development of selective antibody | | | | | | | 1 | 0.28% |
| 12 | of selective antibody therapies | | | | | | | 1 | 0.28% |
| 13 | selective antibody therapies that | | | | | | | 1 | 0.28% |
| 14 | antibody therapies that combat | | | | | | | 1 | 0.28% |
| 15 | misfolded protein diseases at | | | | | | | 1 | 0.28% |
| 16 | protein diseases at the | | | | | | | 1 | 0.28% |
| 17 | diseases at the source | | | | | | | 1 | 0.28% |
| 18 | about our company latest | | | | | | | 1 | 0.28% |
| 19 | our company latest news | | | | | | | 1 | 0.28% |
| 20 | latest news view all | | | | | | | 1 | 0.28% |
| 21 | release apr 30 2024 | | | | | | | 1 | 0.28% |
| 22 | news view all news | | | | | | | 1 | 0.28% |
| 23 | experts is committed to | | | | | | | 1 | 0.28% |
| 24 | all news may 14 | | | | | | | 1 | 0.28% |
| 25 | news may 14 2024 | | | | | | | 1 | 0.28% |
| 26 | may 14 2024 promis | | | | | | | 1 | 0.28% |
| 27 | neurosciences announces first quarter | | | | | | | 1 | 0.28% |
| 28 | announces first quarter 2024 | | | | | | | 1 | 0.28% |
| 29 | first quarter 2024 financial | | | | | | | 1 | 0.28% |
| 30 | quarter 2024 financial results | | | | | | | 1 | 0.28% |
| 31 | 2024 financial results and | | | | | | | 1 | 0.28% |
| 32 | recent highlights view press | | | | | | | 1 | 0.28% |
| 33 | highlights view press release | | | | | | | 1 | 0.28% |
| 34 | 30 2024 promis neurosciences | | | | | | | 1 | 0.28% |
| 35 | press release apr 30 | | | | | | | 1 | 0.28% |
| 36 | view all news may | | | | | | | 1 | 0.28% |
| 37 | skip to main content | | | | | | | 1 | 0.28% |
| 38 | multidisciplinary experts is committed | | | | | | | 1 | 0.28% |
| 39 | amyotrophic lateral sclerosis als | | | | | | | 1 | 0.28% |
| 40 | pipeline addressing neurodegenerative and | | | | | | | 1 | 0.28% |